Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in intestinal ischemia/reperfusion in rats
Copyright © 2020 Elsevier B.V. All rights reserved..
Acute mesenteric ischemia (AMI) is caused by an abrupt cessation of blood flow to the small intestine. Reperfusion is the return of blood flow to the ischemic bowel. Intestinal ischemia/reperfusion (I/R) leads to the formation of reactive oxygen species, local inflammatory response, and may lead to the patient's death. Pre-treatment of the intestinal may reduce the high mortality associated with AMI. 5-Hydroxytryptamine 1B (5-HT1B) and 5-HT1D receptors have anti-inflammatory and neuroprotective effects in different experimental studies. We aimed to investigate the potential involvement of these receptors in intestinal I/R injury. Firstly, we assessed the expression and localization of 5-HT1B and 5-HT1D receptors in the enteric nervous system using an immunofluorescence-based method. Intestinal I/R in rats was induced by 30 min occlusion of superior mesenteric artery and reperfusion for 2 h. Rats were randomly divided in different control and I/R groups (n = 6) receiving either vehicle, sumatriptan (5-HT1B/1D receptors agonist; 0.1 mg/kg), GR127,935 (5-HT1B/1D receptors antagonist; 0.1 mg/kg) and combination of sumatriptan (0.1 mg/kg) + GR127,935 (0.1 mg/kg) before determination of biochemical and histological parameters. In the enteric nervous system, 5-HT1B and 5-HT1D receptors were expressed 17% and 11.5%, respectively. Pre-treatment with sumatriptan decreased 5-hydroxytryptamine (5HT) level by 53%, and significantly decreased calcitonin gene-related peptide (CGRP) levels, lipid pereoxidation, neutrophil infiltration, and level of pro-inflammatory markers in the serum. Histopathologic studies also showed a remarkable decrease in intestinal tissue injury. These findings suggest that sumatriptan may inhibit intestinal injury induced by I/R through modulating the inflammatory response by activation of 5-HT1B/1D receptors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:882 |
|---|---|
| Enthalten in: |
European journal of pharmacology - 882(2020) vom: 05. Sept., Seite 173265 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gharishvandi, Fatemeh [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.05.2021 Date Revised 13.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejphar.2020.173265 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311531695 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311531695 | ||
| 003 | DE-627 | ||
| 005 | 20231225142444.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2020.173265 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311531695 | ||
| 035 | |a (NLM)32574671 | ||
| 035 | |a (PII)S0014-2999(20)30357-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gharishvandi, Fatemeh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in intestinal ischemia/reperfusion in rats |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.05.2021 | ||
| 500 | |a Date Revised 13.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Acute mesenteric ischemia (AMI) is caused by an abrupt cessation of blood flow to the small intestine. Reperfusion is the return of blood flow to the ischemic bowel. Intestinal ischemia/reperfusion (I/R) leads to the formation of reactive oxygen species, local inflammatory response, and may lead to the patient's death. Pre-treatment of the intestinal may reduce the high mortality associated with AMI. 5-Hydroxytryptamine 1B (5-HT1B) and 5-HT1D receptors have anti-inflammatory and neuroprotective effects in different experimental studies. We aimed to investigate the potential involvement of these receptors in intestinal I/R injury. Firstly, we assessed the expression and localization of 5-HT1B and 5-HT1D receptors in the enteric nervous system using an immunofluorescence-based method. Intestinal I/R in rats was induced by 30 min occlusion of superior mesenteric artery and reperfusion for 2 h. Rats were randomly divided in different control and I/R groups (n = 6) receiving either vehicle, sumatriptan (5-HT1B/1D receptors agonist; 0.1 mg/kg), GR127,935 (5-HT1B/1D receptors antagonist; 0.1 mg/kg) and combination of sumatriptan (0.1 mg/kg) + GR127,935 (0.1 mg/kg) before determination of biochemical and histological parameters. In the enteric nervous system, 5-HT1B and 5-HT1D receptors were expressed 17% and 11.5%, respectively. Pre-treatment with sumatriptan decreased 5-hydroxytryptamine (5HT) level by 53%, and significantly decreased calcitonin gene-related peptide (CGRP) levels, lipid pereoxidation, neutrophil infiltration, and level of pro-inflammatory markers in the serum. Histopathologic studies also showed a remarkable decrease in intestinal tissue injury. These findings suggest that sumatriptan may inhibit intestinal injury induced by I/R through modulating the inflammatory response by activation of 5-HT1B/1D receptors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 5-HT1B/1D receptor | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Intestinal ischemia/reperfusion | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a Rat | |
| 650 | 4 | |a Sumatriptan | |
| 650 | 7 | |a Oxadiazoles |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Receptor, Serotonin, 5-HT1B |2 NLM | |
| 650 | 7 | |a Receptor, Serotonin, 5-HT1D |2 NLM | |
| 650 | 7 | |a Serotonin 5-HT1 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Serotonin Antagonists |2 NLM | |
| 650 | 7 | |a GR 127935 |2 NLM | |
| 650 | 7 | |a 2LLH6CEB40 |2 NLM | |
| 650 | 7 | |a Serotonin |2 NLM | |
| 650 | 7 | |a 333DO1RDJY |2 NLM | |
| 650 | 7 | |a Sumatriptan |2 NLM | |
| 650 | 7 | |a 8R78F6L9VO |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
| 650 | 7 | |a JHB2QIZ69Z |2 NLM | |
| 700 | 1 | |a Abdollahi, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Shafaroodi, Hamed |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammad Jafari, Razieh |e verfasserin |4 aut | |
| 700 | 1 | |a Pasalar, Parvin |e verfasserin |4 aut | |
| 700 | 1 | |a Dehpour, Ahmad Reza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 882(2020) vom: 05. Sept., Seite 173265 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
| 773 | 1 | 8 | |g volume:882 |g year:2020 |g day:05 |g month:09 |g pages:173265 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2020.173265 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 882 |j 2020 |b 05 |c 09 |h 173265 | ||